https://news.cision.com/citycon-oyj/r/citycon-oyj-resolved-on-a-directed-share-issue-without-consideration-for-the-payment-of-the-remunera,c4079751  ...
Joint AI Hackathon forms the launchpad for Building New Solutions for Tax and Transfer Pricing Professionals.
LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- GFO-X announces ABN AMRO Clearing, IMC, Standard Chartered Bank and Virtu Financial as strategic partners ahead of launch in Q1 2025.
The Company has resumed technical and financial studies to research the re-start of operations at its Murchison Gold Project. While the Company’s recent focus has been on optimizing production from ...
The 2025 milestones reflect Evaxion’s high activity level, broad pipeline and strong external interest in potential partnerships around both our AI-Immunology™ platform and pipeline assets. As such, ...
Vancouver, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA; FRA:UB10) is pleased to highlight the polymetallic potential of its ...
Robex Resources Inc. ("Robex" or the "Company") (TSXV: RBX) is pleased to announce that the board of directors of the Company has adopted a deferred share unit plan for the Company’s directors (the ...
This is Spryker’s sixth AWS competency, demonstrating its efficiency in the market, deep industry knowledge, and reliable experience in various industry ecosystems. BERLIN and N ...
Deloitte Touche Tohmatsu India LLP acted as exclusive M&A financial advisor to Lumina Datamatics. ICICI Securities acted as exclusive financial advisor to the shareholders of TNQTech. To learn more ...
TI to make advanced royalty payments to license LeddarTech software. QUEBEC CITY, Canada, Dec. 09, 2024 (GLOBE NEWSWIRE) -- LeddarTech ® Holdings Inc. (“LeddarTech”) (Nasdaq: ...
In connection with the collaboration and license agreements with TI and the advanced royalty payments provided thereunder (the “TI Pre-paid Royalty Fee”), LeddarTech entered into: ...
AiViva Biopharma Inc., a clinical-stage biotechnology company, announced the receipt of FDA clearance for testing AIV001 (axitinib) by intradermal injection with their formulation in facial skin.